February 4, 2008
A poster presented by Caroline Sabin from the Royal Free Hospital looked at whether nucleoside analogues were associated with cardiovascular disease (CVD) seen in the large international D:A:D cohort study.1 D:A:D includes over 33,000 patients from 11 prospective cohorts, in which 517 myocardial infarctions (MI) occured over approximately seven years of follow up (157,912 patient years).
This group first reported that ARV treatment as a whole was associated with an increased risk of CVD. Over subsequent years, the study gained more power to look at drug-class effects and last year reported a 110% increased risk per year related to PI use, after adjusting for blood lipids and other metabolic parameters and demogrpahics. No increased risk was seen with use of NNRTIs. This study is now sufficiently powered to look at the impact of some individual ARVs, and in this adjusted multivariate analysis found a 90% increased risk from current or recent use (within six months) of abacavir (RR 1.90, 95%CI 1.47-2.45, p<0.01) and a 49% increased risk with ddI (RR 1.49, 1.14-1.95, p<0.01).
This effect remained after adjustment for viral load, CD4, blood lipids and other metabolic factors'. No link was found with duration of use, or past use of either drug, leading the researchers to conclude that if this effect is causal, the unknown biological mechanism (s) appears reversible after stopping these drugs.
No increased risk was seen with the use of AZT, d4T or 3TC. Exposure to tenofovir or FTC in the cohort was insufficient to include these drugs in the analysis.
Simon Collins is the community representative on the D:A:D Steering Committee.
The poster is available in PDF format from: www.cphiv.dk
These finding are clearly especially important for patients with existing cardiovascular risks. For patients currently stable on treatment, with low cardiovascular risk, or who have limited treatment choices, the benefit of abacavir may still outweigh the additional absolute risk. These decisions clearly should be assessed on an individual case basis.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.